Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Geriatrics Reports
Erschienen in: Current Geriatrics Reports 4/2018

05.11.2018 | Dermatology and Wound Care (C Sayed and D Culton, Section Editors)

Autoimmune Blistering Disorders in the Geriatric Population

verfasst von: Matthew Overton, Donna Culton

Erschienen in: Current Geriatrics Reports | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

In this review, we seek to discuss the pathogenesis, clinical manifestations, treatments, and latest research developments for autoimmune blistering disorders including pemphigus vulgaris (PV) and bullous pemphigoid (BP). We also offer our clinical observations and personal experiences with these conditions as they relate to geriatric patients.

Recent Findings

Recent studies have uncovered important disease associations and new information regarding the pathophysiology of disease. Novel treatments aimed at disease-specific targets hold therapeutic promise.

Summary

Autoimmune blistering disorders are common in the geriatric population and can have a significant impact on overall health and quality of life. Early and accurate diagnosis is critical. Treatment can be challenging given the frequent number of comorbidities in this patient population, but is necessary to reduce morbidity and mortality.
Literatur
1.
•• Pollmann R, Schmidt T, Eming R, Hertl M. Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches. Clin Rev Allergy Immunol. 2018;54(1):1–25 This review provides a comprehensive overview of pemphigus vulgaris. CrossRef
2.
Zhao CY, Murrell DF. Pemphigus vulgaris: an evidence-based treatment update. Drugs. 2015;75(3):271–84.CrossRef
3.
Marazza G, Pham HC, Schärer L, Pedrazzetti PP, Hunziker T, Trüeb RM, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009;161(4):861–8.CrossRef
4.
Lara-Corrales I, Pope E. Autoimmune blistering diseases in children. Semin Cutan Med Surg. 2010;29(2):85–91.CrossRef
5.
Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.CrossRef
6.
Bertram F, Bröcker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7(5):434–40.PubMed
7.
•• Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol. 2018;54(1):26–51 This review highlights important concepts in the diagnosis and treatment of bullous pemphigoid. CrossRef
8.
Sun C, Chang B, Gu H. Non-bullous lesions as the first manifestation of bullous pemphigoid: a retrospective analysis of 24 cases. J Dermatolog Treat. 2009;20(4):233–7.CrossRef
9.
Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28(9):1133–40.CrossRef
10.
Hayashida MZ, Pinheiro JRS, Enokihara MMSS, Vasconcellos MRA. Biologic therapy-induced pemphigus. An Bras Dermatol. 2017;92(4):591–3.CrossRef
11.
Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol. 2011;131(3):637–43.CrossRef
12.
Smith EP, et al. Antigen identification in drug-induced bullous pemphigoid. J Am Acad Dermatol. 1993;29(5 Pt 2):879–82.CrossRef
13.
Kashihara M, Danno K, Miyachi Y, Horiguchi Y, Imamura S. Bullous pemphigoid-like lesions induced by phenacetin. Report of a case and an immunopathologic study. Arch Dermatol. 1984;120(9):1196–9.CrossRef
14.
Hofmann M, Audring H, Sterry W, Trefzer U. Interleukin-2-associated bullous drug dermatosis. Dermatology. 2005;210(1):74–5.CrossRef
15.
Ruocco V, Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol. 1991;30(5):307–12.CrossRef
16.
Lee JJ, Downham TF 2nd. Furosemide-induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol. 2006;5(6):562–4.PubMed
17.
Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol. 2013;149(1):58–62.CrossRef
18.
Patsatsi A, Vyzantiadis TA, Chrysomallis F, Devliotou-Panagiotidou D, Sotiriadis D. Medication history of a series of patients with bullous pemphigoid from northern Greece—observations and discussion. Int J Dermatol. 2009;48(2):132–5.CrossRef
19.
Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care. 2011;34(8):e133.CrossRef
20.
Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26(2):249–53.CrossRef
21.
Varpuluoma O, Försti AK, Jokelainen J, Turpeinen M, Timonen M, Huilaja L, et al. Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish Nationwide Registry study. J Invest Dermatol. 2018;138(7):1659–61.CrossRef
22.
Varpuluoma, O., Försti AK, Jokelainen J, Turpeinen M, Timonen M, Tasanen K,et al Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case control study. J Am Acad Dermatol, 2018.
23.
Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol. 2007;33(1–2):67–77.CrossRef
24.
Ameglio F, D’Auria L, Cordiali-Fei P, Mussi A, Valenzano L, D'Agosto G, et al. Bullous pemphigoid and pemphigus vulgaris: correlated behaviour of serum VEGF, sE-selectin and TNF-alpha levels. J Biol Regul Homeost Agents. 1997;11(4):148–53.PubMed
25.
Rhodes LE, Hashim IA, McLaughlin P, Friedmann PS. Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Derm Venereol. 1999;79(4):288–90.CrossRef
26.
Yamauchi PS, Lowe NJ, Gindi V. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol. 2006;54(3 Suppl 2):S121–2.CrossRef
27.
Nin M, Tokunaga D, Ishii N, Komai A, Hashimoto T, Katoh N. Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept. J Dermatol. 2013;40(1):55–6.CrossRef
28.
Saraceno R, Citarella L, Spallone G, Chimenti S. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol. 2008;33(2):154–5.CrossRef
29.
Monnier-Murina K, du Thanh A, Merlet-Albran S, Guillot B, Dereure O. Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical auto-immune reaction? Dermatology. 2009;219(1):89–90.CrossRef
30.
Boussemart L, Jacobelli S, Batteux F, Goulvestre C, Grange P, Carlotti A, et al. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology. 2010;221(3):201–5.CrossRef
31.
Bordignon M, Belloni-Fortina A, Pigozzi B, Tarantello M, Alaibac M. Bullous pemphigoid during long-term TNF-alpha blocker therapy. Dermatology. 2009;219(4):357–8.CrossRef
32.
Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018;57(6):664–9.CrossRef
33.
Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol. 2011;131(3):631–6.CrossRef
34.
Jedlickova H, Hlubinka M, Pavlik T, Semradova V, Budinska E, Vlasin Z. Bullous pemphigoid and internal diseases—a case-control study. Eur J Dermatol. 2010;20(1):96–101.PubMed
35.
Li L, Chen J, Wang B, Yao Y, Zuo Y. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol. 2009;160(6):1343–5.CrossRef
36.
Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Association between pemphigus and neurologic diseases. JAMA Dermatol. 2018;154(3):281–5.CrossRef
37.
Hsu, D.Y., et al., Association of pemphigus and systemic corticosteroid use with comorbid health disorders: a case-control study. Dermatol Online J, 2017. 23(12).
38.
Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130(8):2041–8.CrossRef
39.
Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57(4):622–8.CrossRef
40.
Werth VP, Fivenson D, Pandya AG, Chen D, Rico MJ, Albrecht J, et al. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2008;144(1):25–32.CrossRef
41.
Hall RP 3rd, Fairley J, Woodley D, Werth VP, Hannah D, Streilein RD, et al. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol. 2015;172(3):760–8.CrossRef
42.
Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol. 2008;144(5):612–6.CrossRef
43.
Du-Thanh A, Merlet S, Maillard H, Bernard P, Joly P, Estève E, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol. 2011;165(6):1337–43.CrossRef
44.
Heilborn JD, Ståhle-Bäckdahl M, Albertioni F, Vassilaki I, Peterson C, Stephansson E. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1999;40(5 Pt 1):741–9.CrossRef
45.
Arnold DF, Burton J, Shine B, Wojnarowska F, Misbah SA. An ‘n-of-1’ placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris. Br J Dermatol. 2009;160(5):1098–102.CrossRef
46.
• Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–40 This landmark study provides rationale for the first-line use of rituximab in the treatment of pemphigus vulgaris. CrossRef
47.
Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148(9):1031–6.CrossRef
48.
Brown, A.E., K. Motaparthi, and S. Hsu, Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients. Dermatol Online J, 2018. 23(12).
49.
Mentink LF, Mackenzie MW, Tóth GG, Laseur M, Lambert FP, Veeger NJ, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol. 2006;142(5):570–6.CrossRef
50.
Cho YT, Chu CY, Wang LF. First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid. Br J Dermatol. 2015;173(1):302–4.CrossRef
Metadaten
Titel
Autoimmune Blistering Disorders in the Geriatric Population
verfasst von
Matthew Overton
Donna Culton
Publikationsdatum
05.11.2018
Verlag
Springer US
Erschienen in
Current Geriatrics Reports / Ausgabe 4/2018
Elektronische ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-018-0265-x

Weitere Artikel der Ausgabe 4/2018

Current Geriatrics Reports 4/2018 Zur Ausgabe

Dermatology and Wound Care (C Sayed and D Culton, Section Editors)

The Impact of Sunlight on Skin Aging

Dermatology and Wound Care (C Sayed and D Culton, Section Editors)

Infestations in the Geriatric Patient

DERMATOLOGY AND WOUND CARE (C SAYED AND D CULTON, SECTION EDITORS)

Treatment of Non-melanoma Skin Cancer in the Elderly

Infectious Diseases in the Elderly (T Rowe, Section Editor)

Vaccinations for Older Adults

Dermatology and Wound Care (C Sayed and D Culton, Section Editors)

Skin Disease and Neurological Conditions of the Elderly

Geriatric Orthopedics (E Meinberg, Section Editor)

Academic Geriatric Orthopedics: a New Paradigm for Inpatient Care

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

23.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Drei Mythen bei der Antibiotikatherapie

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise